ClinConnect ClinConnect Logo
Search / Trial NCT06615609

"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients

Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Sep 24, 2024

Trial Information

Current as of May 14, 2025

Not yet recruiting

Keywords

Smartphone Ai Assisted Cabg Management Metabolic Management Smart Family Doctor

ClinConnect Summary

The "Smart Family Doctor" trial is looking at how a digital health management tool, powered by artificial intelligence, can help improve the control of high blood pressure, diabetes, and cholesterol levels in patients who have recently undergone coronary artery bypass grafting (CABG) surgery. The study will involve around 536 participants from 5 to 10 hospitals and aims to see if this technology can make it easier for patients to manage their health after surgery.

To participate in this trial, you need to be at least 18 years old and have had CABG surgery. You should also have a history of high blood pressure, diabetes, or high cholesterol. If your blood pressure is above certain levels, your blood sugar level (measured by HbA1c) is too high, or your cholesterol levels are not in the healthy range, you may qualify. Participants will need to use a smartphone and provide informed consent to join. This trial is not yet recruiting, so there is no need to take action just yet, but it offers an exciting opportunity to potentially improve health outcomes for patients in similar situations.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years.
  • History of CABG surgery with history of hypertension, diabetes, and dyslipidemia.
  • * At least one of the following criteria is meet:
  • Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg
  • HbA1c no less than 7%
  • LDL-C no less than 1.8 mmol/L
  • Use of a smartphone.
  • Signed informed consent.
  • Exclusion Criteria:
  • History of heart failure or severe arrhythmias.
  • Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency.
  • Pregnancy, lactation, or plans for pregnancy within the next year.
  • Cognitive, communication impairments, or limitations in daily activities.

About China National Center For Cardiovascular Diseases

The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.

Locations

Patients applied

0 patients applied

Trial Officials

Xin Yuan, PhD

Principal Investigator

Chinese Academy of Medical Sciences, Fuwai Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported